BridgeBio Pharma Cash Flow from Financial Activities 2018-2025 | BBIO
BridgeBio Pharma annual/quarterly cash flow from financial activities history and growth rate from 2018 to 2025. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
- BridgeBio Pharma cash flow from financial activities for the quarter ending March 31, 2025 was $0.060B, a 78.42% decline year-over-year.
- BridgeBio Pharma cash flow from financial activities for the twelve months ending March 31, 2025 was $1.357B, a 1.57% increase year-over-year.
- BridgeBio Pharma annual cash flow from financial activities for 2024 was $0.748B, a 65.76% increase from 2023.
- BridgeBio Pharma annual cash flow from financial activities for 2023 was $0.452B, a 3537.91% decline from 2022.
- BridgeBio Pharma annual cash flow from financial activities for 2022 was $-0.013B, a 101.78% decline from 2021.
BridgeBio Pharma Annual Cash Flow Financial
(Millions of US $) |
| 2024 |
$748 |
| 2023 |
$452 |
| 2022 |
$-13 |
| 2021 |
$736 |
| 2020 |
$447 |
| 2019 |
$399 |
| 2018 |
$502 |
| 2017 |
$113 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.426B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
